• Narrow screen resolution
  • Wide screen resolution
  • Decrease font size
  • Default font size
  • Increase font size

ja_mageia

IV Chelation Therapy, Heart Attack Patients and the TACT Trial. What Have We Learned? – An Interview With Gervasio A. Lamas, MD

LamasGervasioHs

Explore the Provocative Findings of IV Chelation Therapy in Post Heart Attack Patients Obtained from the TACT Trial (Trial to Assess Chelation Therapy)

Kirk Hamilton interviews Gervasio A. Lamas, MD Chairman of Medicine at Mount Sinai Medical Center and Chief of the Columbia University Division of Cardiology at Mount Sinai Medical Center. He received his B.A. in Biochemical Sciences cum laude from Harvard College and his M.D. with honors (AOA) from New York University. He completed his Internship and Residency at the Brigham and Women's Hospital of Harvard Medical School, where he later served as Assistant Professor of Medicine. His interests include the treatment and prevention of cardiovascular disease. During the last decade, he has enrolled thousands of patients in more than a dozen U.S. and international trials in order to improve cardiac care and prevent death and disability from heart disease. He presently serves as Co-Chairman for the Occluded Artery Trial (OAT), and Study Chair for the Trial to Assess Chelation Therapy (TACT), a $30 million trial sponsored by the National Institutes of Health. He has authored over 300 scientific publications, and maintains an active clinical practice in Miami Beach and Key Biscayne. He is the co-author of a recent paper published in JAMA, "Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial InfarctionThe TACT Randomized Trial."

Download or Open: Rx2000 Interviews

Dr. Gervasio Lamas Transcripts: Order FREE TRANSCRIPTS Here  More Transcripts

Play Online (38:12 mm:ss):